Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From DBV Technologies

Aimmune's Peanut Immunotherapy Palforzia Gets CHMP Backing

Palforzia will almost certainly be the first treatment to get the green light for peanut allergy in Europe and its new owner will be hoping for a more successful launch than has been seen in the US.

Drug Review Europe

Nestle, Bullish On Palforzia, To Buy Remainder Of Aimmune

Since Palforzia likely will be the only peanut allergy drug on market for some time, Nestle announces it will pay about $2.6bn to acquire the 80% of Aimmune it doesn’t own.

M & A Deals

Keeping Track: Four Novel Agents Clear US FDA, Including Evrysdi, Blenrep

The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Doubts Over DBV's Future As US FDA Rejects Peanut Allergy Patch

The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.

Immune Disorders Drug Review
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule
      • Transdermal
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Biotechnology
    • Large Molecule
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register